Bronchial Biopsy Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Bronchial Biopsy Devices Market is projected to expand from USD 619.55 Million in 2025 to USD 928.21 Million by 2031, reflecting a CAGR of 6.97%. These devices are specialized instruments employed during bronchoscopic procedures to collect pulmonary tissue for the histopathological diagnosis of lung cancer and other respiratory diseases. The market's growth is largely fueled by the rising global incidence of lung malignancies and chronic airway conditions, which create a strong demand for precise, early diagnostic interventions. Furthermore, there is a growing clinical preference for minimally invasive techniques that offer improved safety profiles and reduced hospitalization times compared to open surgeries. Highlighting the urgency of this demand, the American Cancer Society estimated that 234,580 new cases of lung and bronchus cancer would be diagnosed in the United States in 2024.

However, the market faces significant hurdles due to the high costs associated with purchasing and maintaining advanced bronchoscopy systems. In regions with developing healthcare infrastructures, limited reimbursement policies and the substantial capital investment required for these sophisticated tools create financial barriers that restrict widespread adoption. Consequently, these economic constraints may impede market penetration in cost-sensitive areas, even as the prevalence of respiratory conditions requiring biopsy continues to rise.

Market Drivers

The Global Bronchial Biopsy Devices Market is fundamentally driven by the increasing global prevalence of lung cancer and chronic respiratory disorders, which leads to a higher volume of diagnostic bronchoscopies. As the burden of pulmonary malignancies grows, healthcare systems are prioritizing early detection strategies that depend on biopsy devices for tissue acquisition and histological analysis. This rise in disease incidence ensures a sustained demand for biopsy needles, forceps, and brushes to efficiently confirm diagnoses for suspicious nodules. According to the World Health Organization's February 2024 news release, lung cancer was identified as the most common cancer globally, with approximately 2.5 million new cases accounting for 12.4% of all new cancer diagnoses worldwide.

Simultaneously, technological advancements in robot-assisted and navigational bronchoscopy are revolutionizing the market by facilitating access to previously unreachable peripheral lung lesions. Modern platforms employ robotic articulation and electromagnetic navigation to guide biopsy tools with high precision, significantly improving diagnostic yields and reducing the need for invasive surgical biopsies. This technological progress drives market growth by encouraging hospitals to upgrade equipment and enabling pulmonologists to confidently biopsy smaller, early-stage nodules. Reflecting this rapid adoption, Intuitive Surgical reported in October 2024 that procedures using the Ion endoluminal system grew by 73% year-over-year. Additionally, the American Lung Association noted in 2024 that the national lung cancer survival rate increased by 26% over the past five years, underscoring the value of effective biopsy tools.

Market Challenges

A primary obstacle hindering the Global Bronchial Biopsy Devices Market is the significant economic burden associated with acquiring and maintaining these diagnostic systems. High capital costs present a substantial barrier to entry for healthcare facilities, especially in regions with strict budget constraints or inadequate reimbursement frameworks. When hospitals and clinics face financial instability, they often prioritize operational expenses over capital investments, leading to a reluctance to purchase expensive new biopsy instruments. This economic pressure causes a slowdown in the adoption of advanced technology, despite the clear clinical necessity for early lung cancer detection.

Consequently, manufacturers encounter extended sales cycles and reduced market penetration as potential buyers postpone purchasing decisions. In 2024, the American Hospital Association reported that 94 percent of healthcare administrators expected to delay equipment upgrades to manage financial strain. This statistic highlights a widespread trend where financial limitations directly translate into halted modernization of diagnostic capabilities. As providers delay acquiring essential devices to preserve liquidity, demand within the bronchial biopsy market contracts, thereby restricting the widespread utilization of these critical tools in patient care.

Market Trends

The market is currently experiencing an accelerated shift toward single-use disposable bronchoscopes, driven by the critical need to eliminate cross-contamination risks and streamline hospital workflows. Unlike traditional reusable instruments, which involve significant costs for sterilization, repairs, and reprocessing downtime, disposable variants offer immediate availability and a sterile guarantee for every procedure. This transition is further supported by rapid improvements in optical quality and maneuverability, allowing these devices to compete with capital-intensive reusable platforms in intensive care and operating room settings. Evidencing this strong adoption, Ambu A/S reported in November 2024 that its Endoscopy Solutions segment, anchored by its single-use bronchoscopy portfolio, achieved 19.7% organic revenue growth for the 2023/24 financial year.

At the same time, the convergence of artificial intelligence with real-time tomographic imaging is transforming navigational bronchoscopy by addressing the challenge of CT-to-body divergence. Advanced platforms now integrate AI-driven path planning with intraoperative fluoroscopic tomosynthesis to provide pulmonologists with augmented, real-time visual guidance that adjusts for respiratory motion and target displacement during biopsies. This technological synergy allows for the precise targeting of small, peripheral lung nodules that were previously difficult to localize with standard pre-operative CT mapping alone. Highlighting the efficacy of this innovation, Body Vision Medical stated in a June 2024 press release that their AI-powered imaging system demonstrated a diagnostic yield of approximately 90% in bronchoscopic procedures.

Key Players Profiled in the Bronchial Biopsy Devices Market

• OLYMPUS CORPORATION
• Boston Scientific Corporation
• Cook Medical Inc.
• CONMED Corporation
• Medtronic PLC
• Hobbs Medical Inc.
• Telemed Systems Inc.
• Becton Dickinson & Co Ltd.
• Argon Medical Devices Inc.
• Horizons Holdings International Corp

Report Scope

In this report, the Global Bronchial Biopsy Devices Market has been segmented into the following categories:

Bronchial Biopsy Devices Market, by Product:

• Biopsy Forceps (Durability, Disposable, Reusable)
• Transbronchial Needle Aspiration (TBNA) Needles (Conventional, EBUS-TBNA)
• Cytology Brushes

Bronchial Biopsy Devices Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bronchial Biopsy Devices Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.